(NRIX) Nurix Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US67080M1036

Cancer, Autoimmune, Inflammatory, Therapies, BTK, Inhibitors, Partnerships

NRIX EPS (Earnings per Share)

EPS (Earnings per Share) of NRIX over the last years for every Quarter: "2020-02": null, "2020-05": null, "2020-08": -0.59, "2020-11": -0.51, "2021-02": -0.63, "2021-05": -0.6, "2021-08": -0.65, "2021-11": -0.85, "2022-02": -0.95, "2022-05": -1.01, "2022-08": -0.9, "2022-11": -0.87, "2023-02": -0.75, "2023-05": -0.45, "2023-08": -0.68, "2023-11": -0.77, "2024-02": -0.76, "2024-05": -0.71, "2024-08": -0.67, "2024-11": -0.75, "2025-02": -0.67,

NRIX Revenue

Revenue of NRIX over the last years for every Quarter: 2020-02: 2.864, 2020-05: 4.182, 2020-08: 4.085, 2020-11: 6.689, 2021-02: 5.011, 2021-05: 7.091, 2021-08: 10.252, 2021-11: 7.396, 2022-02: 9.621, 2022-05: 11.432, 2022-08: 10.791, 2022-11: 6.783, 2023-02: 12.685, 2023-05: 30.676, 2023-08: 18.467, 2023-11: 15.159, 2024-02: 16.585, 2024-05: 12.092, 2024-08: 12.588, 2024-11: 13.284, 2025-02: 18.453,

Description: NRIX Nurix Therapeutics

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is revolutionizing the treatment of cancer, inflammatory conditions, and other diseases through its innovative small molecule and antibody therapies. With a robust pipeline of promising candidates, the company is poised to make a significant impact in the biotech industry.

The companys lead candidates, including NX-5948, NX-2127, and NX-1607, are demonstrating potential in treating various diseases, from relapsed or refractory B-cell malignancies to autoimmune diseases and immuno-oncology indications. NX-5948, an orally bioavailable BTK degrader, is in Phase 1B/2 clinical trials, while NX-2127, another BTK degrader, is in Phase 1A clinical trials. Meanwhile, NX-1607, a CBL-B inhibitor, is also in Phase 1A clinical trials, targeting immuno-oncology indications.

Nurix Therapeutics has established strategic collaborations with industry giants Gilead Sciences, Sanofi, and Pfizer, which will aid in the co-development and co-commercialization of multiple drug candidates. This collaboration will not only accelerate the development of Nurixs pipeline but also provide the company with significant financial and operational support.

Analyzing the and , we can see that NRIX has been experiencing a significant correction, with its current price at $11.49, down from its 52-week high of $28.14. The stock is currently trading above its SMA20 and SMA50, indicating a potential bullish trend. However, the SMA200 at $17.77 suggests that the stock has significant resistance above its current price. With a market cap of $885.86M USD and a lack of P/E ratio, the company is likely to be valued based on its growth potential.

Forecasting the stocks performance, we can expect NRIX to continue its upward trend if it can break through the $17.77 resistance level. With a robust pipeline and strategic collaborations, the company is well-positioned for long-term growth. However, investors should be cautious of the high volatility, as indicated by the ATR of 0.66, which translates to a 5.76% daily price movement. A potential entry point could be around $10.50, with a stop-loss at $9.50. A successful breakout above $17.77 could see the stock targeting $25-$30 in the short term.

Additional Sources for NRIX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

NRIX Stock Overview

Market Cap in USD 970m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2020-07-24

NRIX Stock Ratings

Growth Rating -49.4
Fundamental -
Dividend Rating 0.0
Rel. Strength -34.5
Analysts 4.44 of 5
Fair Price Momentum 10.63 USD
Fair Price DCF -

NRIX Dividends

Currently no dividends paid

NRIX Growth Ratios

Growth Correlation 3m 66.8%
Growth Correlation 12m -85.2%
Growth Correlation 5y -53.5%
CAGR 5y -8.55%
CAGR/Max DD 5y -0.09
Sharpe Ratio 12m -1.07
Alpha -61.33
Beta 1.873
Volatility 62.67%
Current Volume 565.3k
Average Volume 20d 609.6k
Stop Loss 11.4 (-6.6%)
What is the price of NRIX shares?
As of July 09, 2025, the stock is trading at USD 12.21 with a total of 565,267 shares traded.
Over the past week, the price has changed by +4.27%, over one month by -2.63%, over three months by +31.86% and over the past year by -40.44%.
Is Nurix Therapeutics a good stock to buy?
Probably not. Based on ValueRay´s Analyses, Nurix Therapeutics (NASDAQ:NRIX) is currently (July 2025) not a good stock to buy. It has a ValueRay Growth Rating of -49.40 and therefor a somwhat technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NRIX is around 10.63 USD . This means that NRIX is currently overvalued and has a potential downside of -12.94%.
Is NRIX a buy, sell or hold?
Nurix Therapeutics has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy NRIX.
  • Strong Buy: 10
  • Buy: 6
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for NRIX share price target?
According to our own proprietary Forecast Model, NRIX Nurix Therapeutics will be worth about 12.8 in July 2026. The stock is currently trading at 12.21. This means that the stock has a potential upside of +4.5%.
Issuer Target Up/Down from current
Wallstreet Target Price 30.3 148.4%
Analysts Target Price 30.3 148%
ValueRay Target Price 12.8 4.5%